Highlighting Residual Atherosclerotic Cardiovascular Disease Risk

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Paul M. Ridker, Tom Thurén, Jean MacFadyen et al. · New England Journal of Medicine · 2017 · 9.1K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Anders Olsson, John J.V. McMurray, G Thorgeirsson et al. · The Lancet · 1994 · 8.5K citations

Medicine, Cardiology, Pharmacotherapy +13

The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels

Frank M. Sacks, Marc A. Pfeffer, Lemuel A. Moyé et al. · New England Journal of Medicine · 1996 · 7.5K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes

Christopher P. Cannon, Eugene Braunwald, Carolyn H. McCabe et al. · New England Journal of Medicine · 2004 · 4.9K citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals

Peter Duewell, Hajime Kono, Katey J. Rayner et al. · Nature · 2010 · 3.9K citations · Full text

Life Sciences, Cell Biology, Immunology +12